Newly Diagnosed With Prostate Cancer: First Steps

Prostate cancer decisions run on three inputs. NCI's PDQ summary lists them as the PSA level, the clinical stage, and the Gleason score.

Write all three at the top of your notes. Almost every conversation ahead, including whether to treat at all, comes back to that trio.

For scale, the American Cancer Society projects about 333,830 new US cases and 36,320 deaths for 2026; those are projections, carried on SEER's stat facts page rather than counted by SEER. SEER's own measured figures give a median age at diagnosis of 68. Five-year relative survival for 2016 through 2022 was 100.0% for cancer confined to the prostate, 100.0% when it has reached nearby lymph nodes, and 40.1% once it has spread to distant sites.

The Gleason system scores how abnormal the cells look, on a scale from 2 to 10. Pathologists report it as two numbers added together, such as 3+4=7. The first number describes the most common pattern. The second describes the next most common.

Those two components matter enormously. PDQ maps them onto ISUP grade groups:

• Grade Group 1: Gleason 6 or lower.
• Grade Group 2: Gleason 3+4=7.
• Grade Group 3: Gleason 4+3=7.
• Grade Group 4: Gleason 8.
• Grade Group 5: Gleason 9 or 10.

Read those middle two lines again. A Gleason 7 can be Grade Group 2 or Grade Group 3, depending only on which pattern came first. A report that says "Gleason 7" without the components is incomplete.

Ask for the grade group number. It is the single most useful figure on the pathology report, and it is designed to be compared across patients.

This is the part that separates prostate cancer from most other diagnoses.

PDQ states that many men with localized prostate cancer may die of other illnesses without ever suffering disability from the cancer. It estimates that 30% to 70% of prostate cancers found in men over 60 are clinically indolent, meaning they would never cause harm.

Active surveillance is the formal response. It means monitoring with PSA tests, examinations, imaging, and repeat biopsies, with treatment held in reserve for signs of progression.

PDQ is honest about the limits. It states that active surveillance is appropriate for suitable candidates, while noting that the optimal follow-up strategy is still uncertain. So ask exactly what your surveillance schedule would be, and what specific change would trigger treatment.

If a clinician recommends immediate treatment for Grade Group 1 disease, that is worth a second opinion, not because they are wrong, but because the trade-off deserves a second look.

PDQ sets a threshold for staging studies: a PSA above 20 ng/mL together with a Gleason score above 7, or clinical suspicion that the cancer has spread.

For that group, PSMA PET has changed the picture. PSMA stands for prostate-specific membrane antigen, a protein on prostate cancer cells that a radioactive tracer can attach to.

PDQ reports that PET-CT with the tracer 68Ga-gozetotide found metastatic disease with 85% sensitivity, compared with 38% for conventional imaging. Specificity was 98%, compared with 91%.

That is a large gap. It means conventional bone scan and CT missed the majority of metastatic sites in the compared population. FDA has approved 68Ga-gozetotide and 18F-piflufolastat for initial staging and for evaluating recurrence.

Ask whether PSMA PET is indicated in your case. If it is not, ask what threshold would make it so.

The clearest published accounting of prostate cancer treatment harms comes from the screening evidence. USPSTF quantifies outcomes for 1,000 men aged 55 to 69 screened over 13 years.

Benefits:

• 1.3 men avoid death from prostate cancer.
• 3 men avoid metastatic prostate cancer.

Harms along the way:

• 240 men have at least one positive PSA test.
• 220 men undergo a prostate biopsy.
• 2 men are hospitalized for biopsy complications.
• 100 men are diagnosed with prostate cancer.
• 50 men experience sexual dysfunction caused by treatment.
• 15 men develop urinary incontinence caused by treatment.

Those last two lines are the numbers to carry into a treatment discussion. Among 100 men diagnosed, 50 sexual dysfunction cases and 15 incontinence cases came from the treatment, not the cancer.

That does not argue against treatment. It argues for knowing what you are buying, especially when the alternative is surveillance.

USPSTF grades screening for men aged 55 to 69 as C, meaning the decision should be an individual one. For men 70 and older, it grades PSA screening D, meaning it recommends against it.

The main options PDQ names for localized disease are active surveillance, radical prostatectomy, radiation therapy, and hormonal therapy. Chemotherapy and immunotherapy enter later, in advanced disease.

Useful ways to narrow the choice:

• Get your grade group, PSA, and clinical stage in one written sentence.
• Ask what risk group those three place you in, and what that risk group implies.
• See both a urologist and a radiation oncologist before deciding. They offer different treatments, and hearing both is standard practice, not a challenge to anyone.
• Ask for the surgeon's or center's own outcome figures for continence and erectile function, not published averages.
• Ask whether your case has been or can be reviewed at a multidisciplinary tumor board.

• What is my grade group, and what were the two Gleason components?
• How many biopsy cores were positive, and what percentage of each core was involved?
• What is my clinical stage, and was it based on exam, MRI, or both?
• Which risk group am I in, and would active surveillance be reasonable?
• Do I meet the criteria for PSMA PET?
• If I choose surveillance, what is the exact schedule, and what result would change the plan?
• What are this center's own rates of incontinence and erectile dysfunction after the treatment being proposed?

• https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
• https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
• https://seer.cancer.gov/statfacts/html/prost.html